

32 Bridge, J.A., Birmaher, B., Iyengar, S., et al. 2009. Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder. *Am J Psychiatry*. 166(1):42-9.

Table 1: Characteristics of Placebo-Controlled Trails of Second-Generation Antidepressants in Children and Adolescents with Major Depressive Disorder

| Study | Active Medication, Daily Dose | Year Study Ended | N | Mean Age (years) | Percent Female | Percent White | Percent First Episode |
|--------------------|-------------------------------|------------------|-----|------------------|----------------|---------------|-----------------------|
| Emslie et al. 2007 | Fluoxetine, 20mg | 1995 | 96 | 12.5 | 46 | 79 | 48 |
| Keller et al. 2001 | Paroxetine, 20-40mg | 1997 | 180 | 15.0 | 64 | 82 | 79 |
| Emslie et al. 2002 | Fluoxetine, 20mg | 1999 | 219 | 12.7 | 49 | 82 | 79 |
| Wagner et al. 2003 | Sertraline, 50-200mg | 2001 | 376 | 12.0 | 51 | 70 | 88 |
| TADS Team 2004 | Fluoxetine, 10-40mg | 2003 | 221 | 14.6 | 54 | 74 | 86 |
| Wagner et al. 2004 | Citalopram, 20-40mg | 2001 | 178 | 12.0 | 53 | 77 | 81 |
| Wagner et al. 2006 | Escitalopram, 10-20mg | 2004 | 268 | 12.3 | 52 | 71 | - |
| Berard et al. 2006 | Paroxetine, 20-40mg | 1998 | 286 | 15.6 | 66 | 68 | 70 |
| Emslie et al. 2006 | Paroxetine, 10-50mg | 2001 | 206 | 12.0 | 47 | 79 | 53 |
| Emslie et al. 2007 | Venlafaxine, 37.5-225mg | 2001 | 367 | 12.2 | 46 | 78 | 86 |
| Emslie et al. 2002 | Nefazodone, 100-600mg | 2001 | 206 | 14.7 | 59 | 78 | 73 |
| Dubitsky 2004 | Mirtazapine, 15-45mg | 2000 | 259 | 12.2 | 52 | 81 | - |